Author

Kira Aldrich

Institution: Neurocrine Biosciences (United States)

Observed institution: Neurocrine Biosciences (United States)

OpenAlex ID: A5117063133

Utility and limitations of the FDA adverse events reporting system public dashboard for safety analyses: a case study with vesicular monoamine transporter 2 inhibitors

2025 · Roger S. McIntyre, Shree Karpuram, et al. · Expert Opinion on Drug Safety · 11

VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review

2025 · Amita R. Patel, Robert A. Hauser, et al. · CNS Spectrums · 8

30. Once -daily Valbenazine for Tardive Dyskinesia or Huntington’s Disease Chorea in Patients With Dysphagia

2025 · Roland Jimenez, Mello Hebert, et al. · American Journal of Geriatric Psychiatry

5. Valbenazine Treatment for Tardive Dyskinesia in a 64-year-old Female Presenting With Nonhealing Wounds Due to Truncal Dyskinesia: a Case Report

2025 · Luis Navazo, Samera Taki, et al. · American Journal of Geriatric Psychiatry

Effect Sizes of Once-daily Valbenazine for Tardive Dyskinesia: A Post-hoc Analysis of KINECT® 3 Data (P10-5.017)

2025 · Leslie Citrome, Robert Hauser, et al. · Neurology

Works count: 5

Citation count: 19

H-index: 2

I10-index: 1